Compare · QURE vs RGNX
QURE vs RGNX
Side-by-side comparison of uniQure N.V. (QURE) and REGENXBIO Inc. (RGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. QURE focuses on Biotechnology: Pharmaceutical Preparations, while RGNX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- QURE is the larger of the two at $1.67B, about 5.1x RGNX ($327.8M).
- Over the past year, QURE is up 62.1% and RGNX is down 35.6% - QURE leads by 97.7 points.
- RGNX has been more active in the news (13 items in the past 4 weeks vs 2 for QURE).
- RGNX has more recent analyst coverage (22 ratings vs 20 for QURE).
- Company
- uniQure N.V.
- REGENXBIO Inc.
- Price
- $26.50-1.94%
- $6.32+3.10%
- Market cap
- $1.67B
- $327.8M
- 1M return
- -4.18%
- -40.21%
- 1Y return
- +62.15%
- -35.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 2
- 13
- Recent ratings
- 20
- 22
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Latest QURE
- Director Kaye Jack exercised 2,645 units of Ordinary Shares at a strike of $16.04 and sold $79,376 worth of Ordinary Shares (2,645 units at $30.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by uniQure N.V.
- Amendment: SEC Form SCHEDULE 13G/A filed by uniQure N.V.
- Chief Medical Officer Abi-Saab Walid exercised 25,000 units of Ordinary Shares at a strike of $5.59 and sold $1,127,500 worth of Ordinary Shares (45,000 units at $25.06) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 169,669 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by uniQure N.V.
- Amendment: SEC Form SCHEDULE 13G/A filed by uniQure N.V.
- SEC Form 10-Q filed by uniQure N.V.
- uniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
- uniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest RGNX
- Amendment: SEC Form SCHEDULE 13G/A filed by REGENXBIO Inc.
- SEC Form SC TO-I filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events
- Director Tasse Daniel was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Stump David C was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Zachary Jennifer was granted 9,807 shares, increasing direct ownership by 44% to 31,871 units (SEC Form 4)
- Director Mills Kenneth T. was granted 9,807 shares, increasing direct ownership by 2% to 495,925 units (SEC Form 4)
- Director Migausky George V was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Karabelas Argeris N was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)
- Director Glucksmann Alexandra was granted 9,807 shares, increasing direct ownership by 51% to 28,861 units (SEC Form 4)